#Microbix Biosystems to Release Financial Results for Q3 2026
Microbix Biosystems Inc., a prominent player in the life sciences and diagnostics sector, has announced its schedule for releasing the financial results for the third quarter of fiscal 2026. The company expects to make the financial statements and related disclosures available before the market opens on August 13, 2026.
To further engage stakeholders, Microbix will host a webinar at 10:00 AM ET on the same day, featuring discussions led by its executives including the CEO, CFO, and COO. This session is aimed at providing insights into the quarterly performance and future outlook of the company.
Microbix, headquartered in Mississauga, Ontario, specializes in producing vital components for the diagnostic industry. The company reported revenues of C$ 18.6 million for the last fiscal year, showcasing its role in facilitating the development of diagnostic assays through its proprietary products such as antigens and quality assessment products.
Despite its accomplishments, Microbix has cautioned stakeholders regarding various uncertainties outlined in its forward-looking statements. These include potential risks related to financial performance, production challenges, and fluctuations in market conditions, all of which have the potential to impact its operations moving forward.
Microbix Biosystems Inc. expects to file its financial statements for the third quarter of fiscal 2026, which ended on June 30, 2026, prior to the start of trading on August 13, 2026.
Microbix intends to hold a webinar discussion of its Q3 2026 results featuring its CEO, CFO, and COO. This will take place at 10:00 AM ET on August 13, 2026.
Microbix develops various proprietary biological products, particularly antigens for immunoassays, laboratory quality assessment products (QAPs™), and reference materials (QUANTDx™), aimed at supporting clinical lab proficiency testing and improving diagnostic workflows.
Microbix reported revenues of C$ 18.6 million for its last fiscal year, which was 2025.
Microbix is ISO 9001 & 13485 certified, U.S. FDA registered, Australian TGA registered, and licensed by Health Canada, indicating adherence to international quality and regulatory standards.
Microbix highlights several material risks in its forward-looking statements, including the uncertainty of financial results, product development challenges, potential issues with maintaining adequate working capital, foreign currency risks, and the general unpredictability of market conditions.
Microbix Biosystems Inc. is headquartered in Mississauga, Ontario, Canada.
Microbix is traded on the TSX under the ticker symbol MBX and on the OTCQX under the ticker symbol MBXBF.